Hims & Hers Health has undeniably captured market attention and investor enthusiasm, fueled by a successful Super Bowl ad campaign and its strategic entry into the high-demand GLP-1 weight loss ...

The debate over the ad highlights the ongoing tension between branded pharmaceutical companies and providers of lower-priced generic drugs. Compounded drugs, like those sold by Hims and Hers, do ...

Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health ...

The “Check before you inject” ad specifically calls out compounded medications, which is the type that Hims & Hers manufactures and is not FDA approved. Novo Nordisk blasted its telehealth ...

Telehealth company Hims & Hers has had enough—and is putting its money where its mouth is in the form of its first Super Bowl ad, called “Sick of the System.” The minute-long commercial is ...

Earlier in February, Hims & Hers Health rallied as it was set to debut its controversial Super Bowl ad, where it positioned itself as the “affordable, doctor-trusted, formulated in the US ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why acquisitions boost its outlook.

Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...